Seer Stock

seer.bioHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $108.5MM

Seer is a provider of innovative solutions that act as a gateway to the proteome.

Register To Buy and Sell Shares

For more details on financing and valuation for Seer, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Seer’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Seer.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Robert Langer Ph.D
Co-Founder, Board Member & Chairman of Scientific Advisory Board
Omid Farokhzad MD
Co-Founder, Chief Executive Officer & Board Member
Philip Ma Ph.D
Co-Founder, President & Chief Business Officer

Board Members

Mark McClellan Ph.D
Terrance McGuire
David Hallal
Omid Farokhzad MD
David Singer
Maverick Ventures
Robert Langer Ph.D

News Highlights

Seer Q4 Revenues Grow Nearly Tenfold
The company posted revenues of $3.1 million, up from $336,000 in the year-ago period and beating the consensus Wall Street estimate of $2.2 million.
Seer Collaborators Release Data Indicating Proteograph Platform's Utility for Proteomics Research
The company and its early-access users have recently published data from several studies indicating that its platform can boost plasma proteome coverage.
Seer Q2 Revenues Skyrocket; Firm Inks Chinese Distribution Deal
The company posted revenues of $1.3 million, up from $71,000 in the year-ago period and above the consensus Wall Street estimate of $790,000.
Updated on: Dec 2, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.